Robert S Wallis

Robert S Wallis

UNVERIFIED PROFILE

Are you Robert S Wallis?   Register this Author

Register author
Robert S Wallis

Robert S Wallis

Publications by authors named "Robert S Wallis"

Are you Robert S Wallis?   Register this Author

79Publications

973Reads

50Profile Views

Lung injury on antiretroviral therapy in adults with HIV/TB.

Clin Infect Dis 2019 Jun 26. Epub 2019 Jun 26.

Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciz560DOI Listing
June 2019

Pan-tuberculosis regimens: an argument for.

Lancet Respir Med 2018 04;6(4):239-240

Aurum Institute, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30096-1DOI Listing
April 2018

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Authors:
Robert S Wallis

Eur Respir J 2016 11;48(5):1526-1527

Aurum Institute, Johannesburg, South Africa

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.01207-2016DOI Listing
November 2016

Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review.

Open Forum Infect Dis 2016 Sep 7;3(3):ofw151. Epub 2016 Sep 7.

Division of Infection and Immunity , University College London and NIHR Biomedical Research Centre, UCLH NHS Foundation Trust , United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofw151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084719PMC
September 2016

Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Tuberculosis (Edinb) 2016 05 22;98:92-6. Epub 2016 Mar 22.

Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, 10900 Euclid Ave, Cleveland, OH 44106, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tube.2016.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864490PMC
May 2016

Mathematical Models of Tuberculosis Reactivation and Relapse.

Authors:
Robert S Wallis

Front Microbiol 2016 17;7:669. Epub 2016 May 17.

The Aurum Institute Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2016.00669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869524PMC
May 2016

World TB Day 2016: reflections on the global TB emergency.

Lancet Respir Med 2016 04 23;4(4):249-51. Epub 2016 Mar 23.

Aurum Institute, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(16)00066-7DOI Listing
April 2016

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Lancet Infect Dis 2016 Apr;16(4):e34-46

UNZA-UCLMS Research and Training Project, University Teaching Hospital, Lusaka, Zambia; Centre for Clinical Microbiology, Division of Infection and Immunity, University College London (UCL), London, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(16)00070-0DOI Listing
April 2016

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.

Lancet Infect Dis 2016 Apr;16(4):e47-63

Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(16)00078-5DOI Listing
April 2016

Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.

Clin Infect Dis 2015 Oct;61Suppl 3:S160-3

Certara, LP, St Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/civ612DOI Listing
October 2015

Sputum culture conversion in new TB regimens.

Authors:
Robert S Wallis

Lancet Respir Med 2015 Jun;3(6):e18-9

Aurum Institute, Johannesburg 2193, Gauteng, South Africa; Departments of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Rutgers-New Jersey Medical School, Newark, NJ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(15)00182-4DOI Listing
June 2015

Advancing host-directed therapy for tuberculosis.

Nat Rev Immunol 2015 Apr 13;15(4):255-63. Epub 2015 Mar 13.

Division of AIDS, National Institutes of Health, Bethesda, Maryland 20852, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nri3813
Publisher Site
http://dx.doi.org/10.1038/nri3813DOI Listing
April 2015

Sputum culture conversion as a tuberculosis biomarker: a glass half empty or half full?

Authors:
Robert S Wallis

Lancet Respir Med 2015 Mar 26;3(3):174-5. Epub 2015 Feb 26.

The Aurum Institute, Johannesburg 2193, South Africa. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(15)00058-2DOI Listing
March 2015

Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.

Authors:
Robert S Wallis

Open Forum Infect Dis 2014 Mar 3;1(1):ofu020. Epub 2014 Jun 3.

Aurum Institute , Johannesburg , South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofu020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324181PMC
March 2014

Lack of a therapeutic role for interferon γ in patients with tuberculosis.

Authors:
Robert S Wallis

J Infect Dis 2014 Feb 16;209(4):627-8. Epub 2013 Oct 16.

Old Lyme, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jit555DOI Listing
February 2014

Tuberculosis biomarkers discovery: developments, needs, and challenges.

Lancet Infect Dis 2013 Apr 24;13(4):362-72. Epub 2013 Mar 24.

Specialty Care, Pfizer, Groton, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(13)70034-3DOI Listing
April 2013

Sustainable tuberculosis drug development.

Authors:
Robert S Wallis

Clin Infect Dis 2013 Jan 5;56(1):106-13. Epub 2012 Oct 5.

Clinical Research, Specialty Therapeutics, Pfizer Inc., Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cis849DOI Listing
January 2013

Early bactericidal activity of new drug regimens for tuberculosis.

Lancet 2013 Jan;381(9861):111-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)60041-0DOI Listing
January 2013

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Antimicrob Agents Chemother 2012 Jun 2;56(6):3114-20. Epub 2012 Apr 2.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00384-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370712PMC
June 2012

SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.

J Antimicrob Chemother 2012 May 17;67(5):1163-6. Epub 2012 Jan 17.

Sequella, Inc., Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkr589DOI Listing
May 2012

Biologics and infections: lessons from tumor necrosis factor blocking agents.

Authors:
Robert S Wallis

Infect Dis Clin North Am 2011 Dec;25(4):895-910

Department of Specialty Care, Pfizer, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2011.08.002DOI Listing
December 2011

Pulmonary infectious complications of tumor necrosis factor blockade.

Infect Dis Clin North Am 2010 Sep;24(3):681-92

Pfizer, New London, CT 06320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2010.04.010DOI Listing
September 2010

Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab.

Clin Infect Dis 2010 Jan;50(2):e7-10

Departments of Medicine, University of California, San Diego School of Medicine, San Diego, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/649553DOI Listing
January 2010

Advances in immunotherapy for tuberculosis treatment.

Clin Chest Med 2009 Dec;30(4):769-82, ix

Aurum Institute for Health Research, Suite 300, Private Bag X 30500, Houghton 2041, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccm.2009.08.009DOI Listing
December 2009

Biomarkers of disease activity, cure, and relapse in tuberculosis.

Clin Chest Med 2009 Dec;30(4):783-96, x

Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, 2300 København S, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccm.2009.08.008DOI Listing
December 2009

Infectious complications of tumor necrosis factor blockade.

Authors:
Robert S Wallis

Curr Opin Infect Dis 2009 Aug;22(4):403-9

Pfizer, New London, Connecticut 06320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QCO.0b013e32832dda55DOI Listing
August 2009

Significance of early secreted antigenic target 6-specific T cell depletion after HIV-1 infection.

Authors:
Robert S Wallis

J Infect Dis 2009 Jul;200(1):158; author reply 158-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/599362DOI Listing
July 2009

Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.

Tuberculosis (Edinb) 2009 May 24;89(3):221-4. Epub 2009 Mar 24.

Pfizer Specialty Care, New London, CT 06320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tube.2009.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752959PMC
May 2009

Adalimumab treatment of life-threatening tuberculosis.

Clin Infect Dis 2009 May;48(10):1429-32

Pfizer, New London, Connecticut 06320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/598504DOI Listing
May 2009

Biomarkers for tuberculosis disease status and diagnosis.

Curr Opin Pulm Med 2009 May;15(3):181-7

Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
May 2009

Mycobacterial disease attributable to tumor necrosis factor-alpha blockers.

Authors:
Robert S Wallis

Clin Infect Dis 2008 Dec;47(12):1603-5; author reply 1605-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/593366DOI Listing
December 2008

Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

Clin Infect Dis 2008 Nov;47(10):e83-5

Capital and Coast District Health Board, Wellington, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/592695DOI Listing
November 2008

Acquired rifamycin resistance: pharmacology and biology.

Expert Rev Anti Infect Ther 2008 Apr;6(2):223-30

UMDNJ-NJ Medical School, 1213 N Street NW, Suite A, Washington, DC 20005 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14787210.6.2.223DOI Listing
April 2008

Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.

Authors:
Robert S Wallis

Arthritis Rheum 2008 Apr;58(4):947-52

PPD Inc., Washington, DC 20005, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.23285DOI Listing
April 2008

Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis.

J Antimicrob Chemother 2007 Nov 29;60(5):994-8. Epub 2007 Aug 29.

UMDNJ-New Jersey Medical School, 185 S. Orange Avenue, MSB-185, Newark, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkm291DOI Listing
November 2007

Persistence, not resistance, is the cause of loss of isoniazid effect.

J Infect Dis 2007 Jun;195(12):1870-1; author reply 1872-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/518044DOI Listing
June 2007

Corticosteroids and HIV infection: a review of experience.

Authors:
Robert S Wallis

Curr Opin HIV AIDS 2007 May;2(3):213-8

PPD, Washington, District of Columbia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COH.0b013e3280eec766DOI Listing
May 2007

Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.

Authors:
Robert S Wallis

J Investig Dermatol Symp Proc 2007 May;12(1):16-21

PPD, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.jidsymp.5650031DOI Listing
May 2007

Structural-functional relationships of TNF-alpha antagonists: next steps.

J Investig Dermatol Symp Proc 2007 May;12(1):46-7

Amgen Inc., Thousand Oaks, California 91320-1799, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.jidsymp.5650028DOI Listing
May 2007

Surrogate markers to assess new therapies for drug-resistant tuberculosis.

Authors:
Robert S Wallis

Expert Rev Anti Infect Ther 2007 Apr;5(2):163-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14787210.5.2.163DOI Listing
April 2007

Here today--gone tomorrow: the case for transient acute tuberculosis infection.

Am J Respir Crit Care Med 2006 Oct;174(7):734-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.200607-923EDDOI Listing
October 2006

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.

J Infect Dis 2006 Aug 10;194(4):486-92. Epub 2006 Jul 10.

Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/505430DOI Listing
August 2006

Anti-tuberculosis treatment and infliximab.

Authors:
Robert S Wallis

Respir Med 2005 Dec 21;99(12):1620-2. Epub 2005 Jul 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2005.06.010DOI Listing
December 2005

Reactivation of latent granulomatous infections by infliximab.

Clin Infect Dis 2005 Aug;41 Suppl 3:S194-8

University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/429996DOI Listing
August 2005

Reconsidering adjuvant immunotherapy for tuberculosis.

Authors:
Robert S Wallis

Clin Infect Dis 2005 Jul 31;41(2):201-8. Epub 2005 May 31.

PPD, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/430914DOI Listing
July 2005

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Semin Arthritis Rheum 2005 Apr;34(5 Suppl1):34-8

UMDNJ-New Jersey Medical School, Newark, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2005.01.009DOI Listing
April 2005

Sutton's law.

Authors:
Robert S Wallis

Int J Tuberc Lung Dis 2005 Feb;9(2):233; author reply 233

View Article

Download full-text PDF

Source
February 2005

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture.

Antimicrob Agents Chemother 2004 Aug;48(8):3133-5

University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, USA.

View Article

Download full-text PDF

Source
http://aac.asm.org/cgi/doi/10.1128/AAC.48.8.3133-3135.2004
Publisher Site
http://dx.doi.org/10.1128/AAC.48.8.3133-3135.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC478499PMC
August 2004

Whole blood bactericidal activity during treatment of pulmonary tuberculosis.

J Infect Dis 2003 Jan 6;187(2):270-8. Epub 2003 Jan 6.

Department of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/346053DOI Listing
January 2003